High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial

JAMA

Volumn 294, Issue 19, 2005, Pages 2437-2445

  Pedersen, Terje R ^a   Faergeman, Ole ^b   Kastelein, John J P ^c   Olsson, Anders G ^d   Tikkanen, Matti J ^e   Holme, Ingar ^a   Larsen, Mogens Lytken ^b   Bendiksen, Fredrik S ^{a,b,c,d,e,f,g,h}   Lindahl, Christina ^f   Szarek, Michael ^g   Tsai, John ^h  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f Pfizer Sweden   (Sweden)

^g PFIZER INC   (United States)

^h Pfizer Inc ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; WARFARIN;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; BLOOD CHEMISTRY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EUROPE; FEMALE; HEART ARREST; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOPATHY; NAUSEA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; RHABDOMYOLYSIS; SECONDARY PREVENTION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 27744603499     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.19.2437     Document Type: Article

References (18)

1. Scandinavian Simvastatin Survival Study (4S) Group. Randomized trial of cholesterol-lowering in 4444 patients with coronary-heart-disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Cannon CP, Braunwald E, Mccabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med. 2004;350:1495-1504.
3. Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med. 2005;352:1425-1435.
4. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease: is it time to shift our goals? N Engl J Med. 2005;352:1483-1484.
5. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-1610.
6. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [published correction appears in Circulation. 2004;110:763]. Circulation. 2004;110:227-239.
7. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded End-point (PROBE) study: a novel design for intervention trials. Blood Press. 1992;1:113-119.
8. Pedersen TR, Faergeman O, Kastelein JJP, et al. Design and baseline characteristics of the Incremental Decrease in End Points Through Aggressive Lipid Lowering study. Am J Cardiol. 2004;94:720-724.
9. Cox DR. Regression models and life-tables. J R Stat Soc B Stat Methodol. 1972;34:187.
10. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
11. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum-cholesterol concentration lower risk of ischemic heart disease? BMJ. 1994;308:367-373.
12. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
13. Holme I. Cholesterol reduction and its impact on coronary artery disease and total mortality. Am J Cardiol. 1995;76:10C-17C.
14. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation. 1998;97:946-952.
15. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
16. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study. Circulation. 1998;97:1453-1460.
17. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol. 2004;44:1772-1779.
18. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.